Novel molecular prognostic markers in breast cancer

Expert Opinion on Medical Diagnostics

Volumn 3, Issue 5, 2009, Pages 523-532

  Goswami, Trishna ^b   Shah, Minal ^b   Isaacs, Claudine ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b NONE

Author keywords

21 gene recurrence score; 70 gene prognosis profile; Adjuvant! Online; MammaPrint ; Oncotype DX

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; MOLECULAR MARKER; PLACEBO; TAMOXIFEN;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RISK; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; GENE; HUMAN; MULTIPLE CYCLE TREATMENT; ONLINE ANALYSIS; PROGNOSIS; REVIEW; RISK ASSESSMENT; SCORING SYSTEM;

EID: 77953411672     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530050903032653     Document Type: Review

References (45)

1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365(9472):1687-1717 (Pubitemid 40719106)
2. Smith RE, Bryant J, Decillis A, Anderson S. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 2003;21(7):1195-1204 (Pubitemid 46894010)
3. Goodwin PJ, Ennis M, Pritchard KI, et al. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999;17(8):2365-2370 (Pubitemid 29368234)
4. Oktay K, Oktem O, Reh A, Vahdat L. Measuring the impact of chemotherapy on fertility in women with breast cancer. J Clin Oncol 2006;24(24):4044-4046 (Pubitemid 46630768)
5. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23(31):7811-7819 (Pubitemid 46657378)
6. Vici P, Viola G, Botti C, et al. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients. Clin Ter 2008;159(6):449-452
7. Gasparini G, Pozza F, Harris AL. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 1993;85(15):1206-1219 (Pubitemid 23223526)
8. Hayes DF. Tumor markers for breast cancer. Ann Oncol 1993;4(10):807-819
9. Hayes DF. Tumor markers for breast cancer. Current utilities and future prospects. Hematol Oncol Clin North Am 1994;8(3):485-506
10. Michaelson JS, Silverstein M, Sgroi D, et al. The effect of tumor size and lymph node status on breast carcinoma lethality. Cancer 2003;98(10):2133- 2143 (Pubitemid 37392416)
11. Brouckaert O, Pintens S, Van Belle V, et al. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors. Breast Cancer Res Treat 2009;115(2):349-358
12. Fisher ER, Costantino J, Fisher B, Redmond C. Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol 4). Discriminants for 15-year survival. National Surgical Adjuvant Breast and Bowel Project Investigators. Cancer 1993;71(Suppl 6):2141-2150
13. Fisher B, Jeong JH, Bryant J, et al. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 2004;364(9437):858-868 (Pubitemid 40089466)
14. Tetu B, Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994;73(9):2359-2365
15. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124(7):966-978
16. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25(33):5287-5312
17. Yarbro JW, Page DL, Fielding LP, et al. American Joint Committee on Cancer prognostic factors consensus conference. Cancer 1999;86(11):2436-2446
18. Offersen BV, Alsner J, Ege Olsen K, et al. A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer. Acta Oncol 2008;47(4):618-632 (Pubitemid 351878436)
19. Kute TE, Russell GB, Zbieranski N, et al. Prognostic markers in node-negative breast cancer: a prospective study. Cytometry B Clin Cytom 2004;59(1):24-31 (Pubitemid 38581546)
20. Mirza AN, Mirza NQ, Vlastos G, Singletary SE. Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 2002;235(1):10-26 (Pubitemid 34062395)
21. Janicke F, Prechtl A, Thomssen C, et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001;93(12):913-920 (Pubitemid 32624648)
22. Look MP, van Putten WL, Duffy MJ, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002;94(2):116-128 (Pubitemid 34121291)
23. Di Leo A, Claudino W, Colangiuli, et al. New strategies to identify molecular markers predicting chemotherapy activity and toxicity in breast cancer. Ann Oncol 2007;18(Suppl 12):xii8-14
24. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406(6797):747-752
25. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98(19):10869-10874 (Pubitemid 32878711)
26. Chang HY, Nuyten DS, Sneddon JB, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005;102(10):3738-3743
27. Goetz MP, Suman VJ, Ingle JN, et al. A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin Cancer Res 2006;12(7 Pt 1):2080-2087
28. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19(4):980-991 (Pubitemid 32176272)
29. Olivotto IA, Bajdik CD, Ravdin PM, et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005;23(12):2716-2725 (Pubitemid 46179461)
30. Cronin M, Pho M, Dutta D, et al. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 2004;164(1):35-42 (Pubitemid 38364587)
31. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415(6871):530-536
32. Cobleigh MA, Tabesh B, Bitterman P, et al. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res 2005;11(24 Pt 1):8623-8631 (Pubitemid 43005909)
33. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351(27):2817-2826 (Pubitemid 40051905)
34. Habel LA, Shak S, Jacobs MK, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 2006;8(3):R25 (Pubitemid 43827376)
35. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24(23):3726-3734 (Pubitemid 46622311)
36. Sparano JA. TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer 2006;7(4):347-350 (Pubitemid 44717771)
37. Albain K, Barlow W, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node positive, ER-positive breast cancer (S8814, INT0100). Breast Cancer Res Treat 2007;106:abstr 10
38. Albain KS, Green SJ, Ravdin PM, et al. Adjuvant chemo-hormonal therapy for primary breast cancer should be sequential instead of concurrent; initial results from intergroup trail 0100 (SWOG-8814). Proc Am Soc Clin Oncol 2002;21:abstr 143
39. Mamounas ETG, Bryant J, et al. Association between the 21-gene recurrence score assay (RS) and risk of locoregional failure in node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. Proceedings from the 28th annual San Antonio Breast Cancer Symposium. San Antonio, Texas; 2005
40. Lo SSNJ, Albain KS. Prospective multicenter study of impact of 21-gene Recurrence Score on medical oncologists and patient adjuvant breast cancer treatment selection. J Clin Oncol 2007;25(18S):577
41. Goldstein LJ, Gray R, Badve S, et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 2008;26(25):4063-4071
42. Nimeus-Malmstrom E, Ritz C, Eden P, et al. Gene expression profilers and conventional clinical markers to predict distant recurrences for premenopausal breast cancer patients after adjuvant chemotherapy. Eur J Cancer 2006;42(16):2729-2737 (Pubitemid 44584675)
43. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347(25):1999-2009 (Pubitemid 35461656)
44. Buyse M, Loi S, Van't Veer L, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006;98(17):1183-1192 (Pubitemid 44390989)
45. Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006;355(6):560-569 (Pubitemid 44200649)